LAUSR

461 TO THE EDITOR: We read with interest the recent position statement on the management of non-neurogenic overactive bladder (OAB) published in the Journal. This considered statement reflects recent guidelines from national and international urological societies, including the American Urological Association, the European Association of Urology, the International Continence Society, the Urological Society of Australia and New Zealand and the UroGynaecological Society of Australasia. In recognition of the often repeatedphrase inurological research “the bladder is anunreliablewitness”, there has been an increasing emphasis on addressing factors beyond the bladder when managing patients with OAB and lower urinary tract symptoms (LUTS). The authors of theMJA statement deal with this issue more than most by encouraging their readers to be mindful of known OAB risk factors and comorbid conditions. However, one condition in particular, obstructive sleep apnea (OSA), continues to be overlooked in the diagnosis and management of OAB and LUTS.